<DOC>
	<DOCNO>NCT00710593</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety , tolerability , behavioral impact HPV-6 , -11 , -16 , -18 vaccine HIV-infected young woman .</brief_summary>
	<brief_title>Impact HPV Vaccine HIV-Infected Young Women</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Young woman age 16 year 0 day 23 year 364 day HIVinfection age 9 year document positive result follow licensed test : antibody test confirm Western blot , HIV1 culture , HIV1 DNA PCR , plasma HIV1 RNA &gt; 1,000 copies/ml HIV treatment history fall one follow category : Group A : ART na√Øve ARTexposed , receive HAART least six month prior study entry Group B : Has receive HAART least six month time study entry , two HIV1 RNA plasma viral load &lt; 400 copies/ml two previous clinical visit within 6 month prior study entry Willingness avoid pregnancy study entry Week 28 visit subject childbearing potential , i.e. , use least one barrier hormonal method ; e.g. , condom , DepoProvera , oral contraceptive pill , etc . Subjects ARV medication must use barrier contraceptive method ARV medication make hormonal birth control less effective . Anticipated ability willingness complete study vaccine evaluation Ability willingness participate study provide write informed consent History prior vaccination HPV vaccine Active anogenital wart within three month prior study entry ) history CIN 2/3 ( ever , must document colposcopy ) Previous allergic reaction constituent HPV vaccine Pregnancy Active substance use dependence , opinion site personnel , would interfere adherence study Active opportunistic infection current treatment know suspect active serious bacterial infection time study entry Presence know &gt; Grade 3 clinical laboratory toxicity time study entry ( per ATN Toxicity Tables , see ATN MOGO ) exception isolate Grade 3 serum total hyperbilirubinemia consider due atazanavir ( see Section 9.6 definition isolate total hyperbilirubinemia ) . Receipt routine vaccine within four week prior study entry Receipt immune globulin plasma product within six month prior study entry Receipt blood product transfusion , immune globulin plasma note , within four week prior study entry Receipt restrict medication list Section 5.3.2 within four week precede study entry Receipt disallow medication list Section 5.3.3 within three month precede study entry Thrombocytopenia coagulation disorder would contraindicate intramuscular injection Anticipation longterm systemic corticosteroid therapy ( 10 mg/day prednisone equivalent &gt; 2 consecutive week ) Receipt corticosteroid therapy dose duration within 3 month precede study entry . Use nonsteroidal antiinflammatory agent inhale topical corticosteroid exclusion criterion Known suspected disease immune system ( HIV ) , i.e. , malignancy , current prior treatment malignancy If serious , acute chronic medical surgical condition contraindication present screening , Protocol Team must consult determine whether enrollment may interfere evaluation protocol objective permission proceed enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Adolescent Medicine Trials Network HIV/AIDS Interventions</keyword>
	<keyword>Highly-active antiretroviral therapy</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Reaching Excellence Adolescent Care Health</keyword>
	<keyword>Merck Research Laboratory</keyword>
	<keyword>Telephone Response System</keyword>
</DOC>